Overview

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Status:
Recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

Summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin

Phase:

Phase 3

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Treatments:

Dapagliflozin
Metformin
Pioglitazone